Thu, Sep 18, 2014, 7:39 AM EDT - U.S. Markets open in 1 hr 51 mins


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • justarook04 justarook04 Mar 8, 2014 1:34 PM Flag

    Let's go back 10 months ago (May) and get a very throrough explanation, education and forecast part 1

    From BioMedreports -Scott Matusow"

    Insmed (NASDAQ: INSM) creates inhaled therapies for a number of different lung diseases including chronic lung infections for which there are no approved therapies. What is interesting about the therapy is how it's delivered. Its patented eFlow Electric Nebulizer is a hand-held device that allows the patient to easily inhale from it, so that the antibiotic is delivered directly to the site of infection and into the lungs. The antibiotic agent is a liposomal form of Amikacin called Arikace. Arikace is an antibiotic commonly used by hospitals for severe infections.

    Amikacin is an aminoglycoside antibiotic that is most often used to treat hospital acquired infections with multi-drug resistant gram negative bacteria. Insmed is testing Arikace in several trials for the treatment of Pseudomonas and Non-Tuberculosis Mycobacteria (NTM). The company is currently undergoing a Canadian and European Phase III (CLEAR 108) study for CYSTIC FIBROSIS patients Pseudomonas lung infections, initiated in the 2nd quarter of 2012.

    In a Phase II extension study recommended by the DSMB for Arikace, 560 mg were administered once daily for 28 day periods, for 6 cycles and was well tolerated. No adverse effects were observed with longer term dosing. Data showed statistically significant reduction from baseline in Pseudomonas Aeruginosa density, including mucoid strains. Inhalation of Arikace also showed statistically significant sustained improvement in lung function. Top-line data is expected to be released mid-2013, so investors should be very aware of the therapy's potential.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Amikacin is an aminoglycoside antibiotic that is most often used to treat hospital acquired infections with multi-drug resistant gram negative bacteria."

      From WebMD -

      [ amikacin Inj is used to treat the following:

      Pneumonia caused by the Bacteria Pseudomonas Aeruginosa
      Bacterial Pneumonia caused by Staphylococcus
      Pneumonia caused by E. Coli Bacteria
      Pneumonia caused by Gram-Negative Bacteria
      Pneumonia caused by the Bacteria Serratia
      Pneumonia caused by the Bacteria Enterobacter
      Pneumonia caused by Proteus Bacteria
      Pneumonia caused by Acinetobacter Bacteria
      Pneumonia caused by Bacteria
      Pneumonia Acquired from Being Treated In a Hospital
      Pneumonia in a Newborn

      amikacin Inj may also be used to treat:

      TB involving the Lungs
      Hospital-Acquired Pseudomonas Aeruginosa Pneumonia Treated with Multiple Drugs
      Pneumonia due to the Bacteria Citrobacter Species ]

      This could be the most important driver of Arikace adoption.

      Pulmonologists know all about amikacin. As the Biomedreport suggests, amikacin is currently used only when an infection can't be controlled with first-line antibiotics, which have less systemic toxicity that does amikacin injection.

      How often will pulmonologists use a "New and improved amikacin", which not only has LESS systemic toxicity than the current first-line antibiotics but also delivers an effective concentration to a pulmonary infection far more quickly than anything currently available?

13.29+0.04(+0.30%)Sep 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.